Seeking a measure of clinically meaningful change in ALS

References

• The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase III Study Group. Arch Neurol. 1996;53:1411–47.
   Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Miller RG, Moore DH. ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004; 5 (Suppl 1):90–3.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Ulug AM, Pullman SL, Gooch CL, Chan S, Tang MX, et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology. 2007;68:1402–10.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, et al. The ALSFRS-R predicts survival time in an ALS clinic population. Neurology. 2005;64:38–43.
   PubMedGoogle Scholar
• Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME. Functional outcome measures as clinical trial endpoints in ALS. Neurology. 2004;63:1933–5.
   PubMedGoogle Scholar
• Sorenson E, Windbank AJ, Mandrekar J, Bamlet WR, Appel SH, Armon C, > et al. Subcutaneous IGF-1 is not beneficial in two-year ALS trial. Neurology. 2008;71:1770–5.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Levy G, Montes J, Buchsbaum R, Barsdorf AI, Battista V, et al. Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotroph Lateral Scler. 2007;8:42–6.
   PubMedGoogle Scholar
• Kasarskis EJ, Dempsey-Hall L, Thompson MM, Luu LC, Mendiondo M, Kryscio R. Rating the severity of ALS by caregivers over the telephone using the ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:50–4.
   PubMedGoogle Scholar
• Montes J, Levy G, Albert S, Kaufmann P, Buchsbaum R, Gordon PH, et al. Development and evaluationof a self-administered version of the ALSFRS-R. Neurology. 2006;67:1294–6.
   PubMedGoogle Scholar
• Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson’s disease rating scale. Mov Disord. 2006;21:1200–7.
   PubMedGoogle Scholar
• LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, et al. Adenosine A2A receptor antagonist istradefylline (KW6002) reduces ‘off’ time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial. Ann Neurol. 2008;63:295–302.
   PubMedGoogle Scholar
• Sarna L, Swann S, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, et al. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Radiation Oncology. 2008;72:1378–84.
   PubMed Web of Science ®Google Scholar
• Burback D, Molnar FJ, St John P, ManSonHing M. Key methodological features of randomized controlled trials of Alzheimer’s disease therapy. Minimal clinically important difference, sample size and trial duration. Dement Geriatr Cogn Disord. 1999;10:534–40.
   PubMedGoogle Scholar
• Rockwood K, Fay S, Song X, MacKnight C, Gorman M. Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: a randomized controlled trial. CMAJ. 2006;174:1099–105.
   PubMed Web of Science ®Google Scholar
• Rockwood K, Black S, Bedard MA, Tran T, Lussier I. Specific symptomatic changes following donepezil treatment of Alzheimer’s disease: a multicenter, primary care, open-label study. Int J Geriatr Psychiatry. 2007;22:312–9.
   PubMedGoogle Scholar
• Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, et al. Health related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007;62: 335–46.
   PubMed Web of Science ®Google Scholar
• Scivoletto G, Tamburella F, Laurenza L, Molinari M. The spinal cord independence measure: how much change is clinically significant for spinal cord injury subjects. Disability and Rehabilitation. 2013: Early online 1–6.
   Google Scholar
• Maringwa J, Quinten C, King M, Ringash J, Osoba D, Coens C, et al. Minimal clinically meaningful differences for the EORTC QLQ-30 and EORTC QLQ-BN20 scales in brain cancer patients. Annals of Oncology. 2011;22: 2107–12.
   PubMed Web of Science ®Google Scholar
• Polman C, Rudick R. The Multiple Sclerosis Functional Composite: a clinically meaningful measure of disability. Neurology. 2010;74:S8–15.
   PubMed Web of Science ®Google Scholar
• Doward L, Dietz B, Wilburn J, McKenna S, Bhor M, Rajagopalan R. Impact of Lipoatrophy on Patient Reported Outcome in Antiretroviral Experienced Patients. The AIDS Reader. 2008:242–52.
   Google Scholar
• Raghu G, Collard H, Anstrom K, Flaherty K, Fleming T, King T, et al.Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase III clinical trials. Amer J of Respiratory and Critical Care Medicine. 2012; 185:1044–8.
   PubMed Web of Science ®Google Scholar
• Gordon P. Cheng B, Montes J, Doorish, Albert S, Mitsumoto H. Outcome measures for early phase clinical trials. Amyotroph Lateral Scler. 2007;8:270–3.
   PubMed Web of Science ®Google Scholar
• Kiresuk T, Smith A, Cardillo J, eds. Goal Attainment Scaling: Applications, Theory and Measurement. NJ: Erlbaum, 1994.
   Google Scholar